CPT 88360Laboratory

Tumor immunohistochem/manual

CPT 88360 covers manual tumor immunohistochemistry testing, a specialized laboratory technique that uses antibodies to identify specific proteins in tissue samples to help diagnose cancer types and guide treatment decisions.

Showing rates for

National Average

Base Medicare rate

$115.48

This calculator gives a typical-case estimate using standard Medicare modifier rules. Actual payment depends on payer policies, documentation, code-specific CMS status indicators, and locality. Verify before billing.

RVU breakdown

Work RVU

0.85

PE RVU (NF)

2.7

MP RVU

0.02

Total RVU

3.57

Conversion factor: 32.3465 · Source: CMS MPFS RVU25A · Confidence: High

NCCI bundling edits

Loading bundling edits…

Billing tips

Bill 88360 per antibody stain, not per slide or per case. A panel of 5 antibodies equals 5 units of 88360.
Impact: Underbilling by reporting one unit for multiple antibodies can result in 80% revenue loss on a typical diagnostic panel. With $115.48 per unit, a 5-antibody panel should yield $577.40, not $115.48.
Document each specific antibody by name (e.g., ER, PR, HER2, Ki-67) in the pathology report with interpretation for each.
Impact: Missing antibody-specific documentation is the leading cause of medical necessity denials and audits. Clear documentation supports medical necessity and prevents recoupment averaging 30-40% of submitted charges.
Verify LCD/NCD compliance for specific antibody panels by diagnosis code before performing IHC to ensure coverage.
Impact: Certain antibody combinations are only covered for specific cancer types. Non-covered combinations result in 100% denial. Pre-authorization when required prevents $500-2000 denials per case.
For breast cancer ER/PR/HER2 testing, report 88360 three times but verify payer-specific policies as some require 88342 for HER2.
Impact: Incorrect HER2 coding can result in denial of $115.48 per case or underpayment if 88342's higher rate ($167+) should have been used instead.
Append modifier 26 only when billing professional component separately from an independent technical facility.
Impact: Incorrect modifier 26 use reduces payment by approximately 60-70% if the full global service was performed. Conversely, missing modifier 26 when appropriate causes claim rejection.
Submit detailed special stain requisition forms and clinical indication notes with initial claim to reduce payer requests for medical records.

Live Field Datano reports yet

Real billers contribute denial patterns and appeal strategies for this code. Once 5+ reports come in, you’ll see live aggregated data here — the only place this exists, free.

Working with CPT 88360?

Get the free Revenue Protection Toolkit — the denial triggers, modifier pitfalls, and bundling conflicts that quietly cost you reimbursement. Instant download.

Help build the field knowledge

MedPayIQ gets smarter as billers contribute. If you've had this code denied, share what happened so others learn from it. Anonymous, no patient info.

Related actions

Frequently asked questions

What is the 2025 Medicare reimbursement rate for CPT code 88360?

The 2025 Medicare national average payment rate for CPT 88360 is $115.48 for both facility and non-facility settings. This rate is based on 3.57 total RVUs (0.85 work RVU, 2.7 practice expense RVU, 0.02 malpractice RVU) multiplied by the 2025 conversion factor of 32.3465. Actual payment may vary by geographic locality based on GPCI adjustments.

How many units of 88360 can be billed per specimen?

There is no absolute maximum, as the number of units depends on medical necessity. Each antibody stain performed is reported as one unit of 88360. Typical diagnostic panels range from 2-12 antibodies depending on the clinical scenario. Lymphoma panels may require 10+ antibodies, while metastatic carcinoma workups might use 4-8. Documentation must support the medical necessity for each antibody billed.

What is the difference between CPT 88360 and 88361?

CPT 88360 covers manual tumor immunohistochemistry techniques performed by hand, while 88361 is designated for automated immunohistochemistry using computerized instruments. Both are billed per antibody stain. The distinction is based on methodology: 88360 requires more hands-on technician time and manual processing, whereas 88361 uses automated staining platforms. Reimbursement rates differ, with 88361 typically having lower practice expense RVUs due to automation efficiency.

Can 88360 be billed with surgical pathology codes 88305 or 88307?

Yes, CPT 88360 is separately reportable and not bundled with surgical pathology examination codes 88305 or 88307. Immunohistochemistry represents additional technical and professional work beyond routine histologic examination. Both CPT guidelines and NCCI edits allow separate reporting. Documentation must show IHC was performed in addition to standard H&E microscopic examination and was medically necessary for diagnosis.

What documentation is required to support medical necessity for 88360?

Required documentation includes the clinical indication for testing, specific diagnosis or differential diagnosis necessitating IHC, each antibody performed by name, individual interpretation of results for each stain, and correlation with morphologic findings. The pathology report must demonstrate how IHC results contributed to diagnosis, prognosis, or treatment decisions. Requisition forms should document ordering physician's clinical question and tumor type being evaluated.

Does Medicare cover ER, PR, and HER2 testing using CPT 88360?

Medicare covers ER (estrogen receptor), PR (progesterone receptor), and HER2 immunohistochemistry testing for breast cancer using CPT 88360, with each marker reported separately (3 units total). However, some Medicare contractors and commercial payers require HER2 IHC to be reported with 88342 instead. Always verify local coverage determinations (LCDs) and payer-specific policies. Medical necessity requires documented breast cancer diagnosis with appropriate ICD-10 codes.

What are common reasons for 88360 claim denials?

The most common denial reasons include: insufficient documentation of medical necessity, units exceeding what documentation supports (e.g., billing 6 units but only 4 antibodies documented), inappropriate diagnosis codes not supporting the antibody panel performed, duplicate service edits when same antibody billed multiple times, and missing or incorrect modifiers when billing professional/technical components separately. Lack of individual antibody interpretation in the pathology report is a frequent audit trigger.